Moderators: John R. Lake, MD and Michael H. Nathanson, MD, PhD
Saturday, May 3, 2014, 2–5 p.m.
|Registration Type||On Or Before March 26||After March 26|
This program aims to improve patient care by increasing clinicians’ awareness of recent research that strengthens current clinical care protocols. Investigators will discuss new discoveries that advance the field of hepatology. This program represents a unique opportunity for expert hepatologists to summarize clinical and basic research publications on topics that are highly relevant to the practice of hepatology and liver-based research.
|2 p.m.||Welcome and Introduction|
|2:05 p.m.||Liver Cancer|
|2:35 p.m.||Viral Hepatitis|
|3:05 p.m.||End Stage Liver Disease and Its Complications|
|3:55 p.m.||Liver Transplantation for Viral Hepatitis: New Advances|
|4:25 p.m.||Metabolic Syndrome: Emerging Data Regarding Its Impact on Pre- and Post-Transplant Liver Disease and Outcomes After Liver Transplantation|
- Apply the most recent advances in treatment of viral hepatitis and hepatocellular carcinoma (HCC).
- Use the newest concepts and approaches in liver transplant, including updates on immunosuppression and live donor transplants.
- Practice the most recent advances in the pathogenesis, risk factors and clinical outcomes in non-alcoholic fatty liver disease.
Sunday, May 4, 2014, 8–9:30 a.m.
Monday, May 5, 2013 , 10–11:30 a.m.
The best abstracts in basic and clinical hepatology will be presented at these highly focused sessions.
Are ASH and NASH the Same Disease?
Monday, May 5, 2014, 8–9:30 a.m.
Alcoholic and nonalcoholic fatty liver disease together constitute the most common cause of liver disease in the Western world. The clinical presentation and liver histology in these two entities pose a clinical challenge to clinicians in diagnosing the etiology of fatty liver disease. Furthermore, it is not entirely clear when to subject an individual to a liver biopsy, and how to treat patients with alcoholic steatohepatitis (ASH) and nonalcoholic stetaohepatitis (NASH). Emerging data on the long-term outcomes and treatment modalities for ASH and NASH is refining the management paradigms in these conditions. Therefore, clinicians would like to be advised regarding the differences and similarities in the clinical presentation as well as the management of ASH and NASH.
Early Diagnosis and Treatment of HCC
Monday, May 5, 2014, 2–3:30 p.m.
This activity will educate caregivers of patients with cirrhosis and liver cancer on the recently updated AASLD practice guidelines for HCC. It will give the practitioners practical advice on how to utilize the guidelines to deliver optimal care to their patients with liver disease.
The Gastroenterologist/Hepatologist as a Primary Care Physician: Managing Chronic Diseases
Monday, May 5, 2013, 4–5:30 p.m.
Patients with chronic liver disease or inflammatory bowel disease, and liver transplant recipients, often look to the gastroenterologist/hepatologist as the primary, often sole, provider of their medical care. This care includes wide-ranging issues such as diabetes, cardiovascular disease, hypertension, cancer screening, metabolic bone disease, assessment for surgical procedures and reproductive issues. This clinical symposium will both educate the GI practitioner in non-GI issues in their long-term patients with regard to disease management and discuss when to refer to a specialist.
Preventing Cirrhosis, Regression of Cirrhosis
Monday, May 5, 2013, 4–5:30 p.m.
Over the past 10 years, there have been great strides in liver-directed therapies. For example, safe and effective oral antiviral agents with a high barrier to resistance are widely used to treat patients with chronic hepatitis B. Similarly, a series of potent antiviral agents have recently been approved for patients with HCV and there is growing efficacy data regarding the use of medical, surgical and behavioral therapies for patients with NAFLD. However, there has not been a recent program summarizing the evidence on how these treatments can prevent cirrhosis or even lead to regression in cirrhosis, portal HTN, and the risk for liver cancer. This program will highlight clinical evidence for preventing fibrosis progression.
Keeping Up with Changes in HCV Therapy
Tuesday, May 6, 2014, 8–9:30 a.m.
The purpose of this program is to update clinicians on the rapidly evolving field of hepatitis C therapeutics. The recently approved therapies will be reviewed. The treatment of hepatitis C has undergone a rapid transformation in the past 3 years with the introduction of direct-acting antivirals (DAA) with and without interferon and ribavirin. In January, the first oral regimen for hepatitis C was introduced, and now therapy for genotype 1 hepatitis C may be shortened for 12 weeks. Clinicians will be updated on current treatment guidelines as well as the latest phase 2 and phase 3 data in all hepatitis C populations including treatment naïve , non-responders and special populations. Key phase 3 data from EASL and AASLD will be presented regarding hepatitis C therapy. Finally, a discussion about off label use of available HCV agents in addition to which patients should be treated now versus those who can safely be deferred will ensue and how to help patients decide whether to seek treatment now or defer therapy.
Recurrent Liver Disease Following Liver Transplant
Tuesday, May 6, 2014, 8–9:30 a.m.
Recurrence of the primary liver disease following liver transplantation is one of the leading causes of graft loss and death following liver transplantation. The risk of recurrent disease varies based on the underlying diagnosis, with hepatitis C, hepatocellular carcinoma and NAFLD having higher rates of recurrence and autoimmune, alcoholic and cholestatic liver diseases having lower rates. Understanding the risk factors and treatment options for recurrent disease thus are of paramount importance for clinicians managing liver transplant recipients. This clinical symposium will address the issues for recurrence of common liver diseases after liver transplantation.
Pediatric Liver Disease in the Era of Genomics
(co-sponsored with NASPGHAN)
Tuesday, May 6, 2014, 10–11:30 a.m.
This symposium is designed to increase awareness of the availability and implications of genetic testing for pediatric liver disease in the current era of NextGen sequencing and genomics. The goals are to familiarize the audience with the terminology and testing available and then to discuss the applicability of these tests and data generated to pediatric liver disease now and in the future.
Fatty Liver, Diet and Gut-Barrier Dysfunction
Speaker: Craig J. McClain, MD
Sunday, May 4, 2014, 8–9 a.m.
- Identify the multiple components of the intestinal barrier.
- Recognize how diet can affect the gut barrier.
- Explain how gut-barrier dysfunction can cause fatty liver.
Treatment of Hepatitis C: Interferon-Free at Last
Speaker: Donald M. Jensen, MD
Sunday, May 4, 2014, 10–11 a.m.
- Associate the role and indication for newer antiviral agents in hepatitis C therapy.
- Discover how these new all-oral DAAs may influence the practice of medicine in HCV treatment.
Do We Still Need Liver Biopsy?
Speaker: Nezam H. Afdhal, MD
Sunday, May 4, 2013, 2–3 p.m.
- Discuss the use, indications and limitations of liver biopsy.
- Utilize the new serological and imaging tests use for the staging of liver fibrosis.
- Develop an understanding of the needs and guidelines for the evaluation of liver fibrosis using a multimodality approach.
Is Fatty Liver Disease an Appropriate Indication for Liver Transplantation?
Speaker: Kymberly Watt, MD
Monday, May 5, 2014, 10–11 a.m.
- Review indications for liver transplantation.
- Associate the evolution of NASH and accompanying comorbidities leading up to liver transplantation.
- Examine risk factors and outcomes of patients transplanted with NASH in comparison to other indications.
- Develop post-transplant management plans specific to NASH patients.
Non-Variceal Complications of Cirrhosis
Speaker: Michael B. Fallon, MD
Monday, May 5, 2014, 2–3 p.m
- Recognize the causes and diagnostic features of common non-variceal complications of cirrhosis.
- Define the natural history and impact of non-variceal complications of cirrhosis on outcomes in patients.
- Apply the current state of the art in prevention and therapy of non-variceal complications of cirrhosis.
Other AASLD Programming
Research/Topic Fora, held Sunday, May 4–Tuesday, May 6, 2014, will present opportunities for presentation of original research and exchange of ideas and data. Topics include Autoimmune/cholestatic Liver Disease, Cell and Molecular Biology, Hepatitis B and C, Liver Transplantation, NASH/ASH and Viral hepatitis.
AASLD General Learning Objectives
The AASLD’s general goals and objectives are to:
- Provide a forum for the exchange of new scientific and clinical information relevant to the study of liver disease.
- Create an arena for the interchange of opinions regarding the care and management of all types of liver diseases.
- Assess new diagnostic or therapeutic techniques related to liver disease.